
Vijaya Diagnostic Centre Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Vijaya Diagnostic Centre has seen robust organic growth, with a 20% year-on-year increase excluding PH Pune, driven by volume growth of 20% and footfall growth of 17%.
- Existing centers (as of FY22) continue growing at double-digit rates (~12-13%) with room for further growth over the next 1-2 years.
- New centers added in FY23 and FY24 contribute to accelerated growth, with newer hubs delivering higher patient footfall growth (around 17% in the recent quarter).
- The company expects the double-digit volume and revenue growth to continue, supported by both existing and new centers.
- Expansion focus remains on hubs, especially in Pune and Kolkata, with plans to add 9 new hubs in 12-18 months to sustain growth.
- Long-term growth will rely on both organic expansion in existing centers and adding new capacities in newer geographies.
- EBITDA margins expected to remain stable around 39-40% despite expansion.
See what Vijaya Diagnostic Centre management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company has not indicated any current or planned fundraising through debt or equity.
- Expansion plans for new hub centers in Pune, Kolkata, and adjacent geographies are being funded through internal accruals.
- The management emphasized strong cash reserves (INR212 crores as of Q1 FY'25) to support growth.
- There is no mention of external capital raising, implying reliance on internal resources for ongoing and planned expansions.
See what Vijaya Diagnostic Centre management said on order book — free account, 30 seconds.
Capex plans
Yes- The company has finalized leases for nine new hub locations across home states, Pune, and West Bengal, scheduled to start operations within the next 12 to 18 months.
- Capex per typical hub ranges from INR 12 to 14 crores; for advanced hubs with 3 Tesla MRI and high-end cardiac CT, capex may be INR 18 to 19 crores.
- Expansion in new geographies (Pune, Kolkata, adjacent markets) will be funded from internal accruals.
- The focus is on opening hubs in FY'25, with spokes expected to follow from FY'26 after hubs mature.
- Equipment additions, including advanced diagnostic devices like 3.0 Tesla MRI and 160-slice cardiac CT, are part of the new hubs.
- No material drag expected on overall margins from expansion; EBITDA margins around 39%-40% are sustainable despite aggressive growth plans.
Track Vijaya Diagnostic Centre — get its next earnings analysis in your feed
How does Vijaya Diagnostic Centre rank vs peers in Healthcare Services?
Pro featureHow does Vijaya Diagnostic Centre rank in Healthcare Services?
Compare Vijaya Diagnostic Centre against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Vijaya Diagnostic Centre's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.